MedPath

A Nasal Applicator for the Treatment of Trigeminal Neuralgia

Not Applicable
Completed
Conditions
Trigeminal Neuralgia
Interventions
Device: Nasal ganglion block for TN
Registration Number
NCT01761604
Lead Sponsor
Chicago Anesthesia Pain Specialists
Brief Summary

The pain from Trigeminal Neuralgia (TN) imposes a substantial burden on patients in daily function and reduces quality of life. The sphenopalatine ganglion, located in the posterior part of the middle nasal turbinate, is involved in the pain associated to TN, by blocking the sphenopalatine ganglion relieves patients from the symptoms. However, methods currently in use to accomplish this are either cumbersome for the patient or invasive regarding the puncture of structures.

The purpose of this study is to evaluate the efficacy of Tx360™, a new nasal applicator device, in the treatment of TN. A local anesthetic will be delivered on the ganglion area. We are expecting that this new device will provide at least the same pain relief as the previously described approaches. However, this nasal applicator is intended to be an easy and non invasive method for office use.

Detailed Description

The pain from Trigeminal Neuralgia (TN) imposes a substantial burden on patients in daily function and reduces quality of life. Pain severity correlates with reduced measures of daily functioning, and overall health status.

The sphenopalatine ganglion, located in the posterior part of the middle nasal turbinate, is involved in the pain associated to TN, by blocking the sphenopalatine ganglion relieves patients from the symptoms. However, methods currently in use to accomplish this are either cumbersome for the patient or invasive regarding the puncture of structures.

The purpose of this study is to evaluate the efficacy of Tx360™, a new nasal applicator device, in the treatment of TN. The Tx360™ is a single use nasal applicator that can reach the sphenopalatine ganglion area. It is designed to dispense medications through a flexible canula.

The patients with TN will receive a 0.5 mL spray of local anesthetic on the ganglion area, and measure the change in pain intensity and quality of life.

We are expecting that this new device will provide at least the same pain relief as the previously described approaches. However, this nasal applicator is intended to be an easy and non invasive method for office use.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
10
Inclusion Criteria
  • 18- 80 years old
  • Trigeminal Neuralgia
Exclusion Criteria
  • Nasal septal deformity such as: cleft lip and palate, choanal atresia
  • Septal perforation
  • Recent nasal/midface trauma (< 3 months)
  • Bleeding disorder such as Von Willebrand's disease or hemophilia
  • Severe respiratory distress
  • Neoplasm such as the following: Angiofibroma, sinus Tumors, Granuloma
  • Congestion has been present more than 10 days, fever (define as temperature≥ 100.4 F)
  • Current cocaine user
  • Skin around and inside the nasal passage is dry, cracked, oozing, or bleeding
  • Allergy to marcaine
  • Pregnancy

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Nasal ganglion block for TNNasal ganglion block for TNSphenopalatine ganglion block using the Tx360™ device
Primary Outcome Measures
NameTimeMethod
Pain intensity numeric rating scaleBefore procedure and after procedure

Change in pain intensity before procedure, baseline. And after procedure 15 minutes, 30 minutes, day 1, 7, 14, 21, and 28.

Secondary Outcome Measures
NameTimeMethod
Patient's global impression of changeAfter procedure

Before procedure, baseline. And after procedure 30 minutes, day 1, 7, 14, 21, and 28.

Trial Locations

Locations (1)

Chicago Anesthesia Pain Specialists

🇺🇸

Chicago, Illinois, United States

© Copyright 2025. All Rights Reserved by MedPath